应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01177 中国生物制药
交易中 07-03 13:38:01
2.750
+0.050
+1.85%
最高
2.760
最低
2.690
成交量
1,724万
今开
2.700
昨收
2.700
日振幅
2.59%
总市值
516.76亿
流通市值
516.76亿
总股本
187.91亿
成交额
4,702万
换手率
0.09%
流通股本
187.91亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
中国生物制药(01177)出现大手卖出100万股,成交价$2.71,涉资271万
阿斯达克财经 · 10:19
中国生物制药(01177)出现大手卖出100万股,成交价$2.71,涉资271万
中国生物制药7月2日获南向资金加仓1275.70万股
自选股智能写手 · 09:31
中国生物制药7月2日获南向资金加仓1275.70万股
陈吉宁会见德国勃林格殷格翰全球执行董事会主席冯保和、中国生物制药首席执行长谢承润
澎湃新闻 · 07-02 19:33
陈吉宁会见德国勃林格殷格翰全球执行董事会主席冯保和、中国生物制药首席执行长谢承润
中国生物制药07月02日主力资金流出573万元 连续3日减仓
自选股智能写手 · 07-02 16:15
中国生物制药07月02日主力资金流出573万元 连续3日减仓
中国生物制药(01177)出现大手卖出170万股,成交价$2.6,涉资442万
阿斯达克财经 · 07-02 09:20
中国生物制药(01177)出现大手卖出170万股,成交价$2.6,涉资442万
中国生物制药06月28日遭主力抛售1170万元 环比增加983.33%
自选股智能写手 · 06-28
中国生物制药06月28日遭主力抛售1170万元 环比增加983.33%
中国生物制药(01177)出现大手卖出130万股,成交价$2.68,涉资348.4万
阿斯达克财经 · 06-28
中国生物制药(01177)出现大手卖出130万股,成交价$2.68,涉资348.4万
中国生物制药(01177.HK)跟踪点评:股权激励彰显长期发展信心 创新药管线加速推进
西部证券 · 06-28
中国生物制药(01177.HK)跟踪点评:股权激励彰显长期发展信心 创新药管线加速推进
中国生物制药(01177)上涨5.3%,报2.78元/股
金融界 · 06-26
中国生物制药(01177)上涨5.3%,报2.78元/股
中国生物制药盘中异动 大幅上涨5.26%报2.780港元
自选股智能写手 · 06-26
中国生物制药盘中异动 大幅上涨5.26%报2.780港元
中国生物制药(01177)股价上升5.303%,现价港币$2.78
阿斯达克财经 · 06-26
中国生物制药(01177)股价上升5.303%,现价港币$2.78
大和:上调中国生物制药(01177)评级至“买入” 目标价升至3.2港元
智通财经 · 06-26
大和:上调中国生物制药(01177)评级至“买入” 目标价升至3.2港元
高质量创新成为国产药品开发主旋律,港股创新药ETF(159567)跟踪指数走势占优,中国生物制药、君实生物、来凯医药-B领涨。
有连云 · 06-26
高质量创新成为国产药品开发主旋律,港股创新药ETF(159567)跟踪指数走势占优,中国生物制药、君实生物、来凯医药-B领涨。
中国生物制药现涨近4% 开发药物“利拉鲁肽注射液”获批准上市
新浪港股 · 06-26
中国生物制药现涨近4% 开发药物“利拉鲁肽注射液”获批准上市
中生制药(01177.HK)曾升3% 利拉鲁肽注射液获国家药监局上市批准
阿斯达克财经 · 06-26
中生制药(01177.HK)曾升3% 利拉鲁肽注射液获国家药监局上市批准
港股异动 | 中国生物制药(01177)涨近3% 开发药物“利拉鲁肽注射液”获国家药监局批准上市
智通财经 · 06-26
港股异动 | 中国生物制药(01177)涨近3% 开发药物“利拉鲁肽注射液”获国家药监局批准上市
中国生物制药6月25日获南向资金加仓1510.17万股
自选股智能写手 · 06-26
中国生物制药6月25日获南向资金加仓1510.17万股
多领域展现巨大应用潜力 双抗药物进入“寻宝”竞速赛
第一财经 · 06-25
多领域展现巨大应用潜力 双抗药物进入“寻宝”竞速赛
中国生物制药研发的利拉鲁肽获批上市,GLP-1领域再添一军
21世纪经济报道 · 06-25
中国生物制药研发的利拉鲁肽获批上市,GLP-1领域再添一军
公司概况
公司名称:
中国生物制药
所属市场:
SEHK
上市日期:
--
主营业务:
中国生物制药有限公司是一家主要从事药品业务的投资控股公司。该公司通过三个业务分部进行运营。中药现代制剂及西药分部从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部从事长期及短期投资业务。其他分部主要从事研发活动、向第三方提供服务以及从事相关医疗及医院业务。该公司还通过其子公司从事持有物业、销售健康食品、验光配镜以及零售与批发视光和听力产品业务。
发行价格:
--
{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":2.75,"timestamp":1719985029431,"preClose":2.7,"halted":0,"volume":17239679,"delay":0,"floatShares":18791217230,"shares":18791217230,"eps":0.13451098,"marketStatus":"交易中","marketStatusCode":2,"change":0.05,"latestTime":"07-03 13:38:01","open":2.7,"high":2.76,"low":2.69,"amount":47019720,"amplitude":0.025926,"askPrice":2.76,"askSize":1969000,"bidPrice":2.75,"bidSize":45000,"shortable":3,"etf":0,"ttmEps":0.13451098628799127,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1719994200000},"adr":0,"adjPreClose":2.7,"dividendRate":0.017649,"openAndCloseTimeList":[[1719970200000,1719979200000],[1719982800000,1719993600000]],"volumeRatio":0.673706,"impliedVol":0.3852,"impliedVolPercentile":0.2823,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK"},"requestUrl":"/m/hq/s/01177/wiki","defaultTab":"wiki","newsList":[{"id":"2448146802","title":"中国生物制药(01177)出现大手卖出100万股,成交价$2.71,涉资271万","url":"https://stock-news.laohu8.com/highlight/detail?id=2448146802","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448146802?lang=zh_cn&edition=full","pubTime":"2024-07-03 10:19","pubTimestamp":1719973140,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午10:19出现大手卖出,成交量为100万,成交价为港币$2.71,涉资271万。至目前为止,股价升0.741%,今日最高价为$2.74,而最低价为$2.7,总成交量为601.538万股,总成交金额港币$1.634千万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2407033901/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1521","01177","BK1191","BK1589"],"gpt_icon":0},{"id":"2448711092","title":"中国生物制药7月2日获南向资金加仓1275.70万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448711092","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448711092?lang=zh_cn&edition=full","pubTime":"2024-07-03 09:31","pubTimestamp":1719970293,"startTime":"0","endTime":"0","summary":"7月2日, 南向资金增持中国生物制药1275.70万股。截止当日收盘,港股通共持有中国生物制药206291.27万股,占流通股10.97%。中国生物制药近5个交易日上涨3.85%,港股通累计增持2664.81万股;近20个交易日下跌4.93%,港股通累计增持11564.00万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703094058956a74e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703094058956a74e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1589","BK1521","01177","BK1191"],"gpt_icon":0},{"id":"2448215888","title":"陈吉宁会见德国勃林格殷格翰全球执行董事会主席冯保和、中国生物制药首席执行长谢承润","url":"https://stock-news.laohu8.com/highlight/detail?id=2448215888","media":"澎湃新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448215888?lang=zh_cn&edition=full","pubTime":"2024-07-02 19:33","pubTimestamp":1719919980,"startTime":"0","endTime":"0","summary":"今天下午,上海市委书记陈吉宁会见了德国勃林格殷格翰公司全球执行董事会主席冯保和、中国生物制药有限公司首席执行长谢承润。陈吉宁对勃林格殷格翰与中国生物制药建立战略合作表示祝贺,并介绍了上海生物医药产业发展最新情况。市领导李政参加会见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070219333595662ed5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070219333595662ed5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1191","BK1589","01177","BK1515"],"gpt_icon":0},{"id":"2448821311","title":"中国生物制药07月02日主力资金流出573万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448821311","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448821311?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:15","pubTimestamp":1719908108,"startTime":"0","endTime":"0","summary":"07月02日, 中国生物制药股价涨1.12%,报收2.70元,成交金额8422万元,换手率0.17%,振幅5.62%,量比0.65。中国生物制药今日主力资金净流出573万元,连续3日净流出,上一交易日主力净流出1170万元,今日环比减少51.03%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为55.00%,平均跌幅为2.16%。该股近5个交易日上涨3.46%,主力资金累计净流入17万元;近20日主力资金累计净流出6592万元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021615139ef31683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021615139ef31683&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1515","BK1521","BK1191","01177"],"gpt_icon":0},{"id":"2448001975","title":"中国生物制药(01177)出现大手卖出170万股,成交价$2.6,涉资442万","url":"https://stock-news.laohu8.com/highlight/detail?id=2448001975","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448001975?lang=zh_cn&edition=full","pubTime":"2024-07-02 09:20","pubTimestamp":1719883200,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午09:20出现大手卖出,成交量为170万,成交价为港币$2.6,涉资442万。至目前为止,股价跌2.622%,今日最高价为$2.6,而最低价为$2.6,总成交量为170万股,总成交金额港币$442万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV24070218/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01177","BK1521","BK1589","BK1515","BK1191"],"gpt_icon":0},{"id":"2446527225","title":"中国生物制药06月28日遭主力抛售1170万元 环比增加983.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446527225","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446527225?lang=zh_cn&edition=full","pubTime":"2024-06-28 16:15","pubTimestamp":1719562508,"startTime":"0","endTime":"0","summary":"06月28日, 中国生物制药股价跌1.11%,报收2.67元,成交金额1.05亿元,换手率0.21%,振幅2.59%,量比0.65。中国生物制药今日主力资金净流出1170万元,上一交易日主力净流出108万元,今日环比增加983.33%。该股近5个交易日上涨2.31%,主力资金累计净流出1081万元;近20日主力资金累计净流出4523万元,其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406281615179f6f8729&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406281615179f6f8729&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1521","BK1515","BK1191","BK1589"],"gpt_icon":0},{"id":"2446529892","title":"中国生物制药(01177)出现大手卖出130万股,成交价$2.68,涉资348.4万","url":"https://stock-news.laohu8.com/highlight/detail?id=2446529892","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446529892?lang=zh_cn&edition=full","pubTime":"2024-06-28 14:50","pubTimestamp":1719557400,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在下午02:50出现大手卖出,成交量为130万,成交价为港币$2.68,涉资348.4万。至目前为止,股价跌0.37%,今日最高价为$2.74,而最低价为$2.68,总成交量为2.236千万股,总成交金额港币$6.037千万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2406284842/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01177","BK1515","BK1191","BK1589","BK1521"],"gpt_icon":0},{"id":"2446510005","title":"中国生物制药(01177.HK)跟踪点评:股权激励彰显长期发展信心 创新药管线加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2446510005","media":"西部证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446510005?lang=zh_cn&edition=full","pubTime":"2024-06-28 10:35","pubTimestamp":1719542114,"startTime":"0","endTime":"0","summary":"事件:近期公告计划实施上市以来首次股份激励计划旗下子公司正大天晴计划使用不超过10 亿人民币的自有资金市场回购股份,激励对象包括中高层管理人员及同级别专业人员等;6 月5 日至6 月20 日期间,公司已回购约0.95 亿港元用于后续股份激励计划。加大研发投入,新药管线不断推进。夯实四大治疗领域优势,股权激励彰显信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406281035199f6e0c09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406281035199f6e0c09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1191","BK1161","BK1574","06978","BK1515","01177","BK1589"],"gpt_icon":0},{"id":"2446089339","title":"中国生物制药(01177)上涨5.3%,报2.78元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446089339","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446089339?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:13","pubTimestamp":1719382421,"startTime":"0","endTime":"0","summary":"6月26日,中国生物制药(01177)盘中上涨5.3%,截至14:13,报2.78元/股,成交1.27亿元。中国生物制药有限公司是一家以创新研究和研发驱动的医药集团,主营业务涵盖医药研发、智能化生产和销售,产品在肿瘤、肝病、呼吸系统、外科/镇痛等领域具有优势。公司在全球制药企业中具有显著地位,连续五年入选全球制药企业TOP50,且在股市表现上也有显著成绩,如入选恒生指数成分股和恒生中国企业指数成分股等。截至2023年年报,中国生物制药营业总收入261.99亿元、净利润23.32亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/26141341199496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","BK1515","01177","BK1589","BK1521"],"gpt_icon":0},{"id":"2446331911","title":"中国生物制药盘中异动 大幅上涨5.26%报2.780港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446331911","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446331911?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:13","pubTimestamp":1719382417,"startTime":"0","endTime":"0","summary":"2024年06月26日下午盘14时13分,中国生物制药股票出现波动,股价急速拉升5.26%。中国生物制药股票所在的药品行业中,整体涨幅为0.22%。消息层面,截至14时13分,中国生物制药股票正面舆情新闻比例31.58%。大和预计,中生制药2024财年上半年的收入将约150亿元人民币,相当于同比增长约8%。考虑到正大青岛的处置收益约16亿元人民币,该行预料中生制药2024财年上半年将取得约25亿元盈利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626141338941f14bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626141338941f14bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1191","BK1589","01177","BK1515"],"gpt_icon":0},{"id":"2446331950","title":"中国生物制药(01177)股价上升5.303%,现价港币$2.78","url":"https://stock-news.laohu8.com/highlight/detail?id=2446331950","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446331950?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:13","pubTimestamp":1719382380,"startTime":"0","endTime":"0","summary":"[上升股]中国生物制药(01177) 股价在下午02:13比前收市价上升5.303%,现股价为港币$2.78。至目前为止,今日最高价为$2.78,而最低价为$2.64。总成交量为4.663千万股,总成交金额为港币$1.268亿。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2406261050/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01177","BK1521","BK1515","BK1191","BK1589"],"gpt_icon":0},{"id":"2446382574","title":"大和:上调中国生物制药(01177)评级至“买入” 目标价升至3.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446382574","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446382574?lang=zh_cn&edition=full","pubTime":"2024-06-26 11:43","pubTimestamp":1719373418,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,大和发布研究报告称,鉴于中国生物制药(01177)旗下创新产品销售增加,以及2024至2025财年的业务增长前景可预见度更高。大和将中生制药的目标价由3.1港元上调至3.2港元,评级“跑赢大市”升至“买入”。报告引述管理层表示,公司在创新产品推动下,仍对实现2024财年营业收入及净利润录得同比双位数增长持乐观态度。管理层亦认为,今年下半年的宏观经济环境,将为制药行业提供更具投资性的环境。大和预计,中生制药2024财年上半年的收入将约150亿元人民币,相当于同比增长约8%。考虑到正大青岛的处置收益约16亿元人民币,该行预料中生制药2024财年上半年将取得约25亿元盈利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177"],"gpt_icon":0},{"id":"2446438694","title":"高质量创新成为国产药品开发主旋律,港股创新药ETF(159567)跟踪指数走势占优,中国生物制药、君实生物、来凯医药-B领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446438694","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446438694?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:41","pubTimestamp":1719369706,"startTime":"0","endTime":"0","summary":"2024年6月26日,港股创新药板块领跑港股市场。盘面上,中国生物制药领涨,君实生物、来凯医药-B跟涨,港股创新药ETF市场热度较高,过去5个交易日日均成交额高达5977万元。国联证券表示,高质量创新成为国产药品开发主旋律。进入2024年,创新药首发定价征求意见稿和各地创新药全产业链支持政策文件的出台充分体现了国家对高质量创新药研发的鼓励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1191","01877","688180","BK1161","BK1589","BK1521","BK1583","02105","BK1515"],"gpt_icon":0},{"id":"2446038669","title":"中国生物制药现涨近4% 开发药物“利拉鲁肽注射液”获批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2446038669","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446038669?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:38","pubTimestamp":1719369520,"startTime":"0","endTime":"0","summary":"中国生物制药(01177)早盘上涨3.79%,现报2.74港元,成交额6737.38万港元。\n 中国生物制药公布,该集团开发的“利拉鲁肽注射液”(商品名:贝乐林® )已获得中国国家药品监督管理局的上市批准,用于成人2 型糖尿病患者控制血糖。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-26/doc-inazzmvq0887982.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-26/doc-inazzmvq0887982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1191","01177","BK1521","BK1515","BK1589"],"gpt_icon":0},{"id":"2446385672","title":"中生制药(01177.HK)曾升3% 利拉鲁肽注射液获国家药监局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2446385672","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446385672?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:12","pubTimestamp":1719367920,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 今日高开0.76%,最高见2.72元,一度升3%。现报2.71元,升2.65%,成交1,828.35万股,涉资4,916.81万元。公司开发的“利拉鲁肽注射液”(商品名:贝乐林)已获得中国国家药品监督管理局的上市批准,用于成人2型糖尿病患者控制血糖。公司指,除利拉鲁肽外,亦布局司美格鲁肽,目前正在临床III期,有望为中国数亿糖尿病和肥胖症患者带来福音。(cy/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-25 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132909636_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132909636_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359215/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01477","BK1515","BK1191","BK1521","BK1589","01177","BK1574"],"gpt_icon":0},{"id":"2446383122","title":"港股异动 | 中国生物制药(01177)涨近3% 开发药物“利拉鲁肽注射液”获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2446383122","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446383122?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:05","pubTimestamp":1719367541,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中国生物制药涨近3%,截至发稿,涨2.65%,报2.70港元,成交额4434.88万港元。消息面上,中国生物制药公布,该集团开发的“利拉鲁肽注射液”已获得中国国家药品监督管理局的上市批准,用于成人2 型糖尿病患者控制血糖。2022年中国糖尿病药物市场规模超过人民币600亿元,预计2030年将突破人民币1300亿元。据悉,利拉鲁肽是一种胰高血糖素样肽-1长效类似物,与天然GLP-1具有97%的同源性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","07226","YANG","BK1515","BK1191","HSCEI","BK1589","HSTECH","BK1521"],"gpt_icon":0},{"id":"2446388685","title":"中国生物制药6月25日获南向资金加仓1510.17万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446388685","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446388685?lang=zh_cn&edition=full","pubTime":"2024-06-26 09:31","pubTimestamp":1719365484,"startTime":"0","endTime":"0","summary":"6月25日, 南向资金增持中国生物制药1510.17万股。截止当日收盘,港股通共持有中国生物制药205136.63万股,占流通股10.91%。港股通增持金额前五个股分别为建设银行、中国移动、中国海洋石油、腾讯控股、中国神华。中国生物制药近5个交易日下跌4.00%,港股通累计增持5747.13万股;近20个交易日下跌7.04%,港股通累计增持11569.31万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406260942449f65d4ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406260942449f65d4ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1191","BK1515","01177","BK1589"],"gpt_icon":0},{"id":"2446813440","title":"多领域展现巨大应用潜力 双抗药物进入“寻宝”竞速赛","url":"https://stock-news.laohu8.com/highlight/detail?id=2446813440","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446813440?lang=zh_cn&edition=full","pubTime":"2024-06-25 18:04","pubTimestamp":1719309866,"startTime":"0","endTime":"0","summary":"在上月召开的ASCO2024会议上,多家中国创新药企披露了在研双抗药物的临床数据,其中,康方生物(09926.HK)披露其已上市的双抗药物依沃西在对比K药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的III期临床试验中,呈现出显著优于后者的疗效,成为全球首款在III期单药头对头临床试验中击败K药的创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406253113233195.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202406253113233195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999001176.USD","SG9999014559.SGD","BK1515","SG9999014567.USD","MRK","09926","LU0861579265.USD","LU1720050803.USD","BK4585","IE00BFTCPJ56.SGD","SG9999002232.USD","BK4588","LU1989771016.USD","SG9999001176.SGD","L","LU1989772923.USD","IE0002141913.USD","LU2461242641.AUD","LU0348784397.USD","IE0009355771.USD","LU1093756325.SGD","09966","LU0058720904.USD","01177","SG9999002224.SGD","LU0417516571.SGD","LU2361044949.HKD","IE00BJJMRZ35.SGD","LU0320765489.SGD","BK4559","IE00BJT1NW94.SGD","LU2361045086.USD","BK4516","BK1589","LU1066051498.USD","IE00B1BXHZ80.USD","LU0211331839.USD","LU0053666078.USD","LU2361044865.SGD","BK1161","BK1191","BK4533","LU0122379950.USD","LU1989772840.SGD","IE00BBT3K403.USD","BK4550","LU1917777945.USD","LU2023250504.SGD","LU1066053197.SGD","BK4007"],"gpt_icon":0},{"id":"2446945890","title":"中国生物制药研发的利拉鲁肽获批上市,GLP-1领域再添一军","url":"https://stock-news.laohu8.com/highlight/detail?id=2446945890","media":"21世纪经济报道","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446945890?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:43","pubTimestamp":1719308580,"startTime":"0","endTime":"0","summary":"南方财经6月25日电,港股药企中国生物制药(1177.HK)下属企业正大天晴开发的利拉鲁肽注射液(贝乐林)已获得国家药监局(NMPA)的上市批准,用于成人2型糖尿病患者控制血糖。除利拉鲁肽外,中国生物制药在热门的GLP-1领域还布局了司美格鲁肽注射液以及1类创新药GMA106(GIPR拮抗/GLP-1激动剂)。今年1月,CDE官网公示,正大天晴的司美格鲁肽注射液也已推进至三期临床阶段。据公司相关人士透露,近期将继续推进德谷胰岛素及降糖多肽复方药物产品进度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406251744479f636fb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406251744479f636fb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1589","BK1191","BK1515","01177"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":-0.0391},{"period":"3month","weight":-0.0654},{"period":"6month","weight":-0.1904},{"period":"1year","weight":-0.2054},{"period":"ytd","weight":-0.2135}],"compareEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":-0.0172},{"period":"3month","weight":0.0624},{"period":"6month","weight":0.0675},{"period":"1year","weight":-0.0796},{"period":"ytd","weight":0.0423}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事药品业务的投资控股公司。该公司通过三个业务分部进行运营。中药现代制剂及西药分部从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部从事长期及短期投资业务。其他分部主要从事研发活动、向第三方提供服务以及从事相关医疗及医院业务。该公司还通过其子公司从事持有物业、销售健康食品、验光配镜以及零售与批发视光和听力产品业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.011037},{"month":2,"riseRate":0.666667,"avgChangeRate":0.059327},{"month":3,"riseRate":0.571429,"avgChangeRate":0.043253},{"month":4,"riseRate":0.47619,"avgChangeRate":0.025756},{"month":5,"riseRate":0.714286,"avgChangeRate":0.038694},{"month":6,"riseRate":0.333333,"avgChangeRate":0.000536},{"month":7,"riseRate":0.619048,"avgChangeRate":0.028216},{"month":8,"riseRate":0.35,"avgChangeRate":-0.022888},{"month":9,"riseRate":0.35,"avgChangeRate":-0.024794},{"month":10,"riseRate":0.6,"avgChangeRate":0.037036},{"month":11,"riseRate":0.55,"avgChangeRate":0.076835},{"month":12,"riseRate":0.45,"avgChangeRate":-0.006547}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}